Peter H. O’Donnell

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Jonathan E. Rosenberg, Jean Hoffman‐Censits, Tom Powles et al. · The Lancet · 2016 · 3.7K citations · Full text

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +8

Pan-cancer analysis of whole genomes

Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse et al. · Nature · 2020 · 3.1K citations · Full text

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

Arjun Vasant Balar, Daniel Castellano, Peter H. O’Donnell et al. · The Lancet Oncology · 2017 · 1.3K citations

First-line Pembrolizumab, Urology, Metastatic Urothelial Cancer +7

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 839 citations · Full text

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

Thomas Powles, Peter H. O’Donnell, Christophe Massard et al. · JAMA Oncology · 2017 · 839 citations · Full text